COVID-19: AstraZeneca-Oxford’s Vaccine Shows 70 Per Cent Efficiency in Late-Stage Trials

Summary

  • AstraZeneca said the Covid-19 vaccination, which the firm has been developing along with Oxford University, has shown a 70 per cent efficacy
  • AstraZeneca CEO Pascal Soriot said the results are positive and show that it is highly effective against the coronavirus
  • Andrew Pollard, the chief investigator at Oxford vaccine trial, said one of our dosing schedules showed nearly 90 per cent efficacy

 

In a major development, British-Swedish pharmaceutical giant AstraZeneca Plc (LON: AZN) said the vaccination for the Covid-19, which the firm developed along with Oxford University, has shown a 70 per cent efficacy. 

The results from the clinical trial showed that everyone who was vaccinated in the trial, nearly 70 per cent of them were not infected by the coronavirus. Also, experts had tried two different medication treatments, of which one indicated a better report, close to 90 per cent efficacy. The initial trial results of AstraZeneca marked the fresh development in the battle against the pandemic that has killed almost 1.4 million people around the world and crippled global economy. 

Pascal Soriot, the chief executive officer at AstraZeneca, said in a statement that the latest development is an important milestone in the fight against coronavirus outbreak. The results are positive and show that it is highly effective against the virus and will have an instant effect on the public health emergency.

In the interim clinical trial, AZD1222 in the UK and Brazil revealed the vaccine was extremely effective in stopping Covid-19 diseases. In fact, after the trial, participants did not complain about any side effects which needed any urgent medical assistance or any severe illness.

Meanwhile, Andrew Pollard, the chief investigator at Oxford vaccine trial at Oxford, said the results show that the vaccine can now save many lives, and in fact, the results of one of their dosing schedules showed nearly 90 per cent efficacy.

Now, AstraZeneca is planning to submit the data to the relevant authorities around the world for seeking early or condition approval. AstraZeneca said the firm will seek an emergency use listing from the World Health Organization for an accelerated route to vaccine accessibility in low-income countries.

Also read: AstraZeneca (LON:AZN) to resume COVID-19 vaccine trial in the US ahead of elections?

On 9 September, AstraZeneca had updated the market that the companysuspended the late-stage clinical trial of its Covid-19 vaccine candidate after a volunteer developed an unexplained illness.

On 6 October, the US, Food and Drug Administration (FDA) had issued new guidelines for Covid-19 vaccine developing companies. The new guidance mentioned that the vaccine developers are required to offer at least two months of follow-up for safety data before applying for the authorisation.

Meanwhile, US pharma giants Moderna and Pfizer earlier reported that their initial results of the late stage clinical trials of Covid-19 vaccination have proved nearly 95 per cent efficacy.  

In an official statement, Pfizer stated that the Covid-19 vaccine has shown 95 per cent efficacy on the late stage trial. Moderna also made an announcement saying that its coronavirus vaccine was 94.5 per cent effective in stopping the infection.

 

 

Comment


Disclaimer